



PRESS RELEASE April 11, 2007

## **Martin Nicklasson new CEO and President of Biovitrum**

**The Board of Biovitrum has appointed Martin Nicklasson as the new CEO and President.**

Martin Nicklasson, 52, is currently the CEO of AstraZeneca AB. He is also a member of the executive management of AstraZeneca Plc., where as Executive Vice President, he is head of Global Marketing.

Martin Nicklasson has previously held a number of leadership positions within AstraZeneca, Kabi Pharmacia and Astra. He has a degree in Pharmacy, and a Ph.D. in Pharmaceutical Science. Since 1985 he has been an associate professor at the Faculty of Pharmacy at Uppsala University.

*“Martin Nicklasson is a skilled and experienced executive, and with his background he will be a great asset for Biovitrum. We will continue to focus on strengthening Biovitrum’s position as a leading European biopharma company, and Martin has the requisite experience for leading the development of our broad and balanced product portfolio, and further strengthening Biovitrum’s commercial position. I would also like to express my appreciation for Mats Pettersson, our CEO who is now moving on. Under his leadership, Biovitrum has made a fantastic journey, and the course Mats has set has been critical for getting Biovitrum to the advantageous position it has today,”* says Biovitrum’s Chairman Håkan Åström.

*“After my six years as a CEO, it feels good to be able to step back at a point when the company is standing strong, with excellent prospects for the future. It has been a fantastic time, and I believe that Biovitrum’s strong development will continue under Martin Nicklasson’s leadership,”* says Biovitrum’s parting CEO Mats Pettersson.

*“As the new CEO, I am very eager to get started with the plans to further develop Biovitrum as a new Swedish biopharma company. Today the company has a solid position with many opportunities to be even stronger in the future. I have followed Biovitrum for a number of years, and my impression is that the company has a rich potential. Biovitrum has also conducted a successful public listing, and I see it as a key objective to further develop the company and its personnel and thus create value for the company’s shareholders,”* says Martin Nicklasson, Biovitrum’s next CEO.

Mats Pettersson will remain as CEO until Martin Nicklasson assumes his position on May 14.

**For more information, please contact:**

**Biovitrum AB (publ)**

Håkan Åström, Chairman of the Board

Cell phone: +46 70 374 72 13

[hakanastrom@aol.com](mailto:hakanastrom@aol.com)

Anna Karin Källén, Vice President, Corporate Communications

Phone: +46 8 697 2085, Cell phone: +46 73 433 20 85

[annakarinn.kallen@biovitrum.com](mailto:annakarinn.kallen@biovitrum.com)

**About Biovitrum**

Biovitrum is one of the largest biopharma companies in Europe. With operations in Sweden and in the UK Biovitrum conducts research and develops pharmaceuticals for unmet medical needs both for common diseases and conditions that affect smaller patient populations. Biovitrum has a broad and balanced R&D portfolio with several projects in clinical and preclinical phases for the treatment of obesity, diabetes, inflammation and eye and blood diseases as well as a number of well defined niche indications. Biovitrum develops and produces protein-based drugs on a contractual basis and markets a range of specialist pharmaceuticals primarily in the Nordic countries. Biovitrum has revenues of approximately SEK 1.2 billion and 550 employees. Biovitrum is listed on the Stockholm Stock Exchange since September 15, 2006. For more information see [www.biovitrum.com/](http://www.biovitrum.com/)